Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Carcinoma, Renal Cell × belzutifan × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

von Hippel-Lindau Disease 2 Pheochromocytoma 1 Paraganglioma 1 Kidney Neoplasms 1 Carcinoma, Renal Cell 1 Adenoma, Islet Cell 1

Interventions

Sunitinib 6 pembrolizumab 3 Nivolumab 3 cabozantinib 2 Ipilimumab 2 Everolimus 2 Axitinib 2 sacituzumab govitecan 1 lenvatinib 1 entrectinib 1 belzutifan 1 avelumab 1 Sorafenib 1 Saline Solution 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡